Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomark... by Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino

Get full text

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer by Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Francesca Corti, Elisabetta Fenocchio, Massimiliano Salati, Margherita Ambrosini, Michael J Overman, Lisa Salvatore, Rossana Intini, Priya Jayachandran, Javier Ros, Maria Elena Elez, Marwan Fakih, Aakash Tushar Shah, Rosalba Miceli, Monica Niger, Vincenzo Nasca, Giacomo Mazzoli, Francesco Barretta

Get full text

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical tr... by Takayuki Yoshino, Josep Tabernero, Jin Yao, Amit Mahipal, Eric Chen, Heinz-Josef Lenz, Aparna Parikh, Timothy Larson, Dustin Deming, David R Spigel, Allen L Cohn, Mark Kochenderfer, Elena Elez, Spencer H Shao, Regan Holdridge, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell

Get full text

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers by Peter Gallagher, Christian Rolfo, Elena Elez, Julien Taieb, Jennifer Houlden, Linda Collins, Corran Roberts, Thierry André, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Vlad Popovici, Alberto Bardelli, Robbie Carson, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Bryan T. Hennessy, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

Get full text

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) by Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

Get full text

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors by Michael Hoffmeister, Hermann Brenner, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Julien Taieb, David Tougeron, Robyn L Ward, Marco Vitellaro, Thierry André, Pierre Laurent-Puig, Jitendra Jonnagaddala, Francesca Bergamo, Raghav Sundar, Claire Gallois, Michael J Overman, Jakob Nikolas Kather, Lisa Salvatore, Romain Cohen, Rossana Intini, Priya Jayachandran, Miriam Koopman, Javier Ros, Marwan Fakih, Vincenzo Nasca, Giacomo Mazzoli, Jeanine M L Roodhart, Filippo Ghelardi, Elena Elez, Durgesh Wankhede, Marta Ligero, Joseph Zhao, Koen Zwart, Jeroen Derksen, Nicholas Hawkins, Javier Carmona

Get full text